The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The FDA has approved the use of nivolumab (Opdivo) with ipilimumab (Yervoy) in adult and pediatric patients age 12 or older ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) ...

Bristol Myers Squibb’s Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer: Princeton, N.J. Thursday, April ...

Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Eating certain combinations of food additives may lead to a slightly increased risk of type 2 diabetes, according to results ...

The Food and Drug Administration announced it has approved nivolumab, or Opdivo, marketed by Bristol Myers (BMY) Squibb, with ipilimumab, or ...

US pharma major Bristol Myers Squibb has received full approval from the US Food and Drug Administration for the use of ...

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of ...